Wuhu Zhang Heng Chun Pharmaceutical

Anhui Zhanghengchun Pharmaceutical is a traditional Chinese medicine (TCM) pharmaceutical company with a history dating back to 1800. Headquartered in Wuhu, Anhui Province, China, the company specializes in the research, development, manufacturing, and sale of Chinese patent medicines across various formulations, including pills, tablets, capsules, and granules. Its commercial product portfolio features well-known traditional remedies such as Liuwei Dihuang Wan, Xiaochaihu granules, and proprietary products like Hengzhi Kechuan capsules and Shiqiwei Tianjing capsules. In its innovative R&D pipeline, the company is advancing Ginkgo total lactone dropping pills, which have undergone Phase 3 clinical trials for the treatment of ischemic stroke. The company was successfully listed on China's National Equities Exchange and Quotations (NEEQ) system in November 2024.